We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PEP:NASDAQPepsiCo, Inc. Analysis

Data as of 2026-05-22 - not real-time

$148.85

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

PepsiCo trades at $148.85, roughly 68% above its DCF‑derived fair value of $88.74, suggesting the stock is currently overvalued despite a solid fundamentals backdrop. The company delivers strong earnings growth (forward EPS of $9.15 versus trailing $6.37), an 8.5% revenue expansion, and a robust ROE of 44%, while maintaining a 3.98% dividend yield backed by an 89% payout ratio and healthy free cash flow. Technicals are mixed: the 20‑day SMA (152.97) sits above the price, the RSI at 39 hints at slight oversold pressure, yet the MACD remains bearish, and volume is trending higher near the $146.38 support level. Recent news highlights a dividend increase to $1.48 per share and a strategic pivot toward health‑conscious products, reinforcing the dividend appeal but also underscoring the need for volume‑driven growth to justify the premium.
Given the defensive consumer sector positioning, low beta, and increasing liquidity, the downside risk is limited, but the valuation gap and bearish momentum temper short‑term upside expectations. Investors may consider holding for dividend income while monitoring earnings momentum and any price correction toward intrinsic value.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near support at $146.38
  • Bearish MACD histogram
  • Attractive dividend yield of ~4%

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Consistent revenue growth and high ROE
  • Strategic shift toward healthier product lines
  • Valuation premium relative to DCF

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong cash generation and dividend sustainability
  • Brand resilience in consumer defensive sector
  • Long‑term growth upside from health‑focused portfolio expansion

Key Metrics & Analysis

Financial Health

Revenue Growth8.50%
Profit Margin9.15%
P/E Ratio23.4
ROE43.88%
ROA9.09%
Debt/Equity244.84
P/B Ratio9.5
Op. Cash Flow$13.1B
Free Cash Flow$8.7B

Technical Analysis

TrendNeutral
RSI39.2
Support$146.38
Resistance$160.00
MA 20$152.97
MA 50$154.25
MA 200$150.60
MACDBearish
VolumeIncreasing
Fear & Greed Index91.39

Valuation

Fair Value$88.74
Target Price$171.05
Upside/Downside14.91%
GradeOvervalued
TypeGrowth
Dividend Yield3.98%

Risk Assessment

Beta-0.03
Volatility18.84%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.